BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kastrup J. Can YKL-40 be a new inflammatory biomarker in cardiovascular disease? Immunobiology 2012;217:483-91. [DOI: 10.1016/j.imbio.2011.04.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Pawlak K, Rozkiewicz D, Mysliwiec M, Pawlak D. YKL-40 in hemodialyzed patients with and without cardiovascular complications – The enhancement by the coexistence of the seropositivity against hepatitis C virus infection. Cytokine 2013;62:75-80. [DOI: 10.1016/j.cyto.2013.02.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
2 El-asrar MA, Elbarbary NS, Ismail EAR, Elshenity AM. Serum YKL-40 in young patients with β-thalassemia major: Relation to hepatitis C virus infection, liver stiffness by transient elastography and cardiovascular complications. Blood Cells, Molecules, and Diseases 2016;56:1-8. [DOI: 10.1016/j.bcmd.2015.09.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
3 Qin G, Li X, Chen Z, Liao G, Su Y, Chen Y, Zhang W. Prognostic Value of YKL-40 in Patients with Glioblastoma: a Systematic Review and Meta-analysis. Mol Neurobiol 2017;54:3264-70. [PMID: 27090900 DOI: 10.1007/s12035-016-9878-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
4 Hosbond SE, Diederichsen ACP, Saaby L, Rasmussen LM, Lambrechtsen J, Munkholm H, Sand NPR, Gerke O, Poulsen TS, Mickley H. Can osteoprotegerin be used to identify the presence and severity of coronary artery disease in different clinical settings? Atherosclerosis 2014;236:230-6. [DOI: 10.1016/j.atherosclerosis.2014.07.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
5 Bastrup-Birk S, Skjoedt MO, Munthe-Fog L, Strom JJ, Ma YJ, Garred P. Pentraxin-3 serum levels are associated with disease severity and mortality in patients with systemic inflammatory response syndrome. PLoS One. 2013;8:e73119. [PMID: 24039869 DOI: 10.1371/journal.pone.0073119] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 5.2] [Reference Citation Analysis]
6 Tan H, Yao H, Lie Z, Chen G, Lin S, Zhang Y. MicroRNA‑30a‑5p promotes proliferation and inhibits apoptosis of human pulmonary artery endothelial cells under hypoxia by targeting YKL‑40. Mol Med Rep 2019;20:236-44. [PMID: 31115541 DOI: 10.3892/mmr.2019.10251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
7 Kim HM, Lee BW, Song YM, Kim WJ, Chang HJ, Choi DH, Yu HT, Kang E, Cha BS, Lee HC. Potential association between coronary artery disease and the inflammatory biomarker YKL-40 in asymptomatic patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2012;11:84. [PMID: 22809439 DOI: 10.1186/1475-2840-11-84] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
8 Riabov V, Gudima A, Wang N, Mickley A, Orekhov A, Kzhyshkowska J. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol 2014;5:75. [PMID: 24634660 DOI: 10.3389/fphys.2014.00075] [Cited by in Crossref: 244] [Cited by in F6Publishing: 263] [Article Influence: 30.5] [Reference Citation Analysis]
9 Wang XY, Zhang F, Zhang C, Zheng LR, Yang J. The Biomarkers for Acute Myocardial Infarction and Heart Failure. Biomed Res Int 2020;2020:2018035. [PMID: 32016113 DOI: 10.1155/2020/2018035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
10 Zhang Y, Gao H, Li H, Guo J, Ouyang B, Wang M, Xu Q, Wang J, Lv M, Guo X, Liu Q, Wei L, Ren H, Xi Y, Guo Y, Ren B, Pan S, Liu C, Ding X, Xiang H, Yu Y, Song Y, Meng L, Liu S, Wang J, Jiang Y, Shi J, Liu S, Sabir JSM, Sabir MJ, Khan M, Hajrah NH, Ming-Yuen Lee S, Xu X, Yang H, Wang J, Fan G, Yang N, Liu X. The White-Spotted Bamboo Shark Genome Reveals Chromosome Rearrangements and Fast-Evolving Immune Genes of Cartilaginous Fish. iScience 2020;23:101754. [PMID: 33251490 DOI: 10.1016/j.isci.2020.101754] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
11 Hjort M, Eggers KM, Lindhagen L, Baron T, Erlinge D, Jernberg T, Marko-Varga G, Rezeli M, Spaak J, Lindahl B. Differences in biomarker concentrations and predictions of long-term outcome in patients with ST-elevation and non-ST-elevation myocardial infarction. Clin Biochem 2021:S0009-9120(21)00229-0. [PMID: 34496288 DOI: 10.1016/j.clinbiochem.2021.09.001] [Reference Citation Analysis]
12 Sun Y, Kong X, Wu S, Ma L, Yan Y, Lv P, Jiang L. YKL-40 as a new biomarker of disease activity in Takayasu arteritis. Int J Cardiol 2019;293:231-7. [PMID: 31303395 DOI: 10.1016/j.ijcard.2019.06.058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Harutyunyan M, Gøtze JP, Winkel P, Johansen JS, Hansen JF, Jensen GB, Hilden J, Kjøller E, Kolmos HJ, Gluud C, Kastrup J. Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial. Immunobiology 2013;218:945-51. [PMID: 23294528 DOI: 10.1016/j.imbio.2012.10.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
14 Song CL, Bin-Li, Diao HY, Wang JH, Shi YF, Lu Y, Wang G, Guo ZY, Li YX, Liu JG, Wang JP, Zhang JC, Zhao Z, Liu YH, Li Y, Cai D, Li Q. Diagnostic Value of Serum YKL-40 Level for Coronary Artery Disease: A Meta-Analysis. J Clin Lab Anal 2016;30:23-31. [PMID: 27152377 DOI: 10.1002/jcla.21804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 González-Muniesa P, Marrades MP, Martínez JA, Moreno-Aliaga MJ. Differential proinflammatory and oxidative stress response and vulnerability to metabolic syndrome in habitual high-fat young male consumers putatively predisposed by their genetic background. Int J Mol Sci 2013;14:17238-55. [PMID: 23975165 DOI: 10.3390/ijms140917238] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
16 Böckelmann LC, Felix T, Calabrò S, Schumacher U. YKL-40 protein expression in human tumor samples and human tumor cell line xenografts: implications for its use in tumor models. Cell Oncol (Dordr) 2021;44:1183-95. [PMID: 34432260 DOI: 10.1007/s13402-021-00630-z] [Reference Citation Analysis]
17 Arain F, Gullestad L, Nymo S, Kjekshus J, Cleland JG, Michelsen A, McMurray JJ, Wikstrand J, Aukrust P, Ueland T. Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). Biomarkers 2017;22:261-7. [PMID: 27325138 DOI: 10.1080/1354750X.2016.1204003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
18 Gao M, Wei Y, Xu Q, Ji R, Han Z, Jiang T. Elevated serum YKL-40 correlates with clinical characteristics in patients with polymyositis or dermatomyositis. Ann Clin Biochem 2019;56:95-9. [DOI: 10.1177/0004563218786979] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
19 Chen XL, Li Q, Huang WS, Lin YS, Xue J, Wang B, Jin KL, Shao B. Serum YKL-40, a prognostic marker in patients with large-artery atherosclerotic stroke. Acta Neurol Scand 2017;136:97-102. [PMID: 27650381 DOI: 10.1111/ane.12688] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
20 Yang L, Dong H, Lu H, Liao Y, Zhang H, Xu L, Tan Y, Cao S, Tan J, Fu S. Serum YKL-40 predicts long-term outcome in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Medicine (Baltimore) 2019;98:e14920. [PMID: 30896649 DOI: 10.1097/MD.0000000000014920] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Harutyunyan M, Johansen JS, Mygind ND, Reuter SB, Kastrup J. Serum YKL-40 for monitoring myocardial ischemia after revascularization in patients with stable coronary artery disease. Biomark Med 2014;8:977-87. [PMID: 25343670 DOI: 10.2217/bmm.14.20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
22 Kim KY, Ahn Y, Kim DY, Kim H, Kim DS. Elevated serum YKL-40 levels in patients with Kawasaki disease. Biomarkers 2017;22:326-30. [DOI: 10.1080/1354750x.2016.1265000] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
23 Chen G, Yang T, Gu Q, Ni X, Zhao Z, Ye J, Meng X, Liu Z, He J, Xiong C. Elevated plasma YKL-40 as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension: YKL-40 predicts outcomes in PAH. Respirology 2014;19:608-15. [DOI: 10.1111/resp.12283] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
24 Foroughi M, Mohammadi Z, Majidi Tehrani M, Bakhtiari M, Dabbagh A, Haji Molahoseini M. The Effect of Erythropoietin Administration on the Serum Level of YKL-40, pro-BNP and IL-6 in Coronary Surgery Patients. Iran J Pharm Res 2020;19:430-9. [PMID: 33680042 DOI: 10.22037/ijpr.2020.112867.13993] [Reference Citation Analysis]
25 Mygind ND, Axelsson A, Ruwald MH, Dalsgaard M, Steffensen R, Iversen K, Johansen JS, Kastrup J. The inflammatory biomarker YKL-40 decreases stepwise after exercise stress test. Cardiovasc Endocrinol 2016;5:21-7. [PMID: 28392973 DOI: 10.1097/XCE.0000000000000073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Steinhaeuser SS, Morera E, Budkova Z, Schepsky A, Wang Q, Rolfsson O, Riedel A, Krueger A, Hilmarsdottir B, Maelandsmo GM, Valdimarsdottir B, Sigurdardottir AK, Agnarsson BA, Jonasson JG, Ingthorsson S, Traustadottir GA, Oskarsson T, Gudjonsson T. ECM1 secreted by HER2-overexpressing breast cancer cells promotes formation of a vascular niche accelerating cancer cell migration and invasion. Lab Invest 2020;100:928-44. [PMID: 32203150 DOI: 10.1038/s41374-020-0415-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Zhang M, Yan L, Lippi G, Hu ZD. Pleural biomarkers in diagnostics of malignant pleural effusion: a narrative review. Transl Lung Cancer Res 2021;10:1557-70. [PMID: 33889529 DOI: 10.21037/tlcr-20-1111] [Reference Citation Analysis]
28 Çetin M, Erdoğan T, Kırış T, Özer S, Çinier G, Emlek N, Durak H, Şatıroğlu Ö. Elevated serum YKL40 level is a predictor of MACE during the long-term follow up in hypertensive patients. Clin Exp Hypertens 2020;42:271-4. [PMID: 31204510 DOI: 10.1080/10641963.2019.1632342] [Reference Citation Analysis]
29 Jefri M, Huang YN, Huang WC, Tai CS, Chen WL. YKL-40 regulated epithelial-mesenchymal transition and migration/invasion enhancement in non-small cell lung cancer. BMC Cancer 2015;15:590. [PMID: 26275425 DOI: 10.1186/s12885-015-1592-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 5.1] [Reference Citation Analysis]
30 Kjaergaard AD, Johansen JS, Bojesen SE, Nordestgaard BG. Observationally and Genetically High YKL-40 and Risk of Venous Thromboembolism in the General Population: Cohort and Mendelian Randomization Studies. Arterioscler Thromb Vasc Biol 2016;36:1030-6. [PMID: 26988593 DOI: 10.1161/ATVBAHA.116.307251] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
31 Seo J, Ahn Y, Zheng Z, Kim BO, Choi MJ, Bang D, Kim DY. Clinical significance of serum YKL-40 in Behçet disease. Br J Dermatol 2016;174:1337-44. [PMID: 26708309 DOI: 10.1111/bjd.14376] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
32 Yang X, Sheng G. YKL-40 levels are associated with disease severity and prognosis of viral pneumonia, but not available in bacterial pneumonia in children. BMC Pediatr 2018;18:381. [PMID: 30514252 DOI: 10.1186/s12887-018-1345-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
33 Chaocharoen W, Suginta W, Limbut W, Ranok A, Numnuam A, Khunkaewla P, Kanatharana P, Thavarungkul P, Schulte A. Electrochemical detection of the disease marker human chitinase-3-like protein 1 by matching antibody-modified gold electrodes as label-free immunosensors. Bioelectrochemistry 2015;101:106-13. [PMID: 25203453 DOI: 10.1016/j.bioelechem.2014.07.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
34 Xu Y, Wang Q, Liu Y, Cui R, Lu K, Zhao Y. Association between Helicobacter pylori infection and carotid atherosclerosis in patients with vascular dementia. J Neurol Sci 2016;362:73-7. [PMID: 26944122 DOI: 10.1016/j.jns.2016.01.025] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
35 Mygind ND, Iversen K, Køber L, Goetze JP, Nielsen H, Boesgaard S, Bay M, Johansen JS, Nielsen OW, Kirk V, Kastrup J. The inflammatory biomarker YKL-40 at admission is a strong predictor of overall mortality. J Intern Med 2013;273:205-16. [PMID: 23140269 DOI: 10.1111/joim.12006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
36 Palomer X, Pizarro-Delgado J, Vázquez-Carrera M. Emerging Actors in Diabetic Cardiomyopathy: Heartbreaker Biomarkers or Therapeutic Targets? Trends Pharmacol Sci 2018;39:452-67. [PMID: 29605388 DOI: 10.1016/j.tips.2018.02.010] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
37 Dieset I, Mørch RH, Hope S, Hoseth EZ, Reponen EJ, Gran JM, Aas M, Michelsen AE, Reichborn-Kjennerud T, Nesvåg R, Agartz I, Melle I, Aukrust P, Djurovic S, Ueland T, Andreassen OA. An association between YKL-40 and type 2 diabetes in psychotic disorders. Acta Psychiatr Scand 2019;139:37-45. [PMID: 30328100 DOI: 10.1111/acps.12971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
38 Nagpure A, Choudhary B, Gupta RK. Chitinases: in agriculture and human healthcare. Crit Rev Biotechnol 2014;34:215-32. [PMID: 23859124 DOI: 10.3109/07388551.2013.790874] [Cited by in Crossref: 63] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
39 Baran A, Myśliwiec H, Szterling-Jaworowska M, Kiluk P, Świderska M, Flisiak I. Serum YKL-40 as a potential biomarker of inflammation in psoriasis. J Dermatolog Treat 2018;29:19-23. [PMID: 28498006 DOI: 10.1080/09546634.2017.1330529] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
40 Wang F, Li W, Liu Z, Yu R, Wang D. LPS-induced inflammatory response and apoptosis are mediated by Fra-1 upregulation and binding to YKL-40 in A549 cells. Exp Ther Med 2021;22:1474. [PMID: 34737814 DOI: 10.3892/etm.2021.10909] [Reference Citation Analysis]
41 Uysal P, Durmus S, Sozer V, Gelisgen R, Seyhan EC, Erdenen F, Simsek G, Uzun H. YKL-40, Soluble IL-2 Receptor, Angiotensin Converting Enzyme and C-Reactive Protein: Comparison of Markers of Sarcoidosis Activity. Biomolecules 2018;8:E84. [PMID: 30154391 DOI: 10.3390/biom8030084] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
42 Hartmann P, Schober A, Weber C. Chemokines and microRNAs in atherosclerosis. Cell Mol Life Sci 2015;72:3253-66. [PMID: 26001902 DOI: 10.1007/s00018-015-1925-z] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 5.9] [Reference Citation Analysis]
43 Keles ZP, Keles GC, Avci B, Cetinkaya BO, Emingil G. Analysis of YKL-40 Acute-Phase Protein and Interleukin-6 Levels in Periodontal Disease. Journal of Periodontology 2014;85:1240-6. [DOI: 10.1902/jop.2014.130631] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
44 Laucyte-Cibulskiene A, Ward LJ, Ebert T, Tosti G, Tucci C, Hernandez L, Kautzky-Willer A, Herrero MT, Norris CM, Pilote L, Söderberg M, Brismar TB, Ripsweden J, Stenvinkel P, Raparelli V, Kublickiene K; GOING-FWD Consortium. Role of GDF-15, YKL-40 and MMP 9 in patients with end-stage kidney disease: focus on sex-specific associations with vascular outcomes and all-cause mortality. Biol Sex Differ 2021;12:50. [PMID: 34526107 DOI: 10.1186/s13293-021-00393-0] [Reference Citation Analysis]
45 Iłżecki M, Iłżecka J, Przywara S, Terlecki P, Grabarska A, Stepulak A, Zubilewicz T. Effect of carotid endarterectomy on brain damage markers. Acta Neurol Scand 2017;135:352-9. [PMID: 27126899 DOI: 10.1111/ane.12607] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
46 Maegdefessel L, Spin JM, Raaz U, Eken SM, Toh R, Azuma J, Adam M, Nakagami F, Heymann HM, Chernogubova E, Jin H, Roy J, Hultgren R, Caidahl K, Schrepfer S, Hamsten A, Eriksson P, McConnell MV, Dalman RL, Tsao PS. miR-24 limits aortic vascular inflammation and murine abdominal aneurysm development. Nat Commun 2014;5:5214. [PMID: 25358394 DOI: 10.1038/ncomms6214] [Cited by in Crossref: 124] [Cited by in F6Publishing: 126] [Article Influence: 15.5] [Reference Citation Analysis]
47 Jin Y, Cao JN, Wang CX, Feng QT, Ye XH, Xu X, Yang CJ. High serum YKL-40 level positively correlates with coronary artery disease. Biomark Med 2017;11:133-9. [PMID: 28097894 DOI: 10.2217/bmm-2016-0240] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
48 Pala S, Sari M, Kahveci G, Alizade E, Arslantas U, Uslu A. Plasma YKL-40 Elevation on Admission and Follow-Up Is Associated with Diastolic Dysfunction and Mortality in Patients with Acute Myocardial Infarction. Cardiol Res Pract 2018;2018:8701851. [PMID: 29686891 DOI: 10.1155/2018/8701851] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
49 Tsantilas P, Lao S, Wu Z, Eberhard A, Winski G, Vaerst M, Nanda V, Wang Y, Kojima Y, Ye J, Flores A, Jarr KU, Pelisek J, Eckstein HH, Matic L, Hedin U, Tsao PS, Paloschi V, Maegdefessel L, Leeper NJ. Chitinase 3 like 1 (CHI3L1) is a regulator of smooth muscle cell physiology and atherosclerotic lesion stability. Cardiovasc Res 2021:cvab014. [PMID: 33471078 DOI: 10.1093/cvr/cvab014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
50 Thomsen SB, Rathcke CN, Jørgensen NB, Madsbad S, Vestergaard H. Effects of Roux-en-Y gastric bypass on fasting and postprandial levels of the inflammatory markers YKL-40 and MCP-1 in patients with type 2 diabetes and glucose tolerant subjects. J Obes 2013;2013:361781. [PMID: 24303210 DOI: 10.1155/2013/361781] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
51 Erfan G, Guzel S, Alpsoy S, Rifaioglu EN, Kaya S, Kucukyalcın V, Topcu B, Kulac M. Serum YKL-40: a potential biomarker for psoriasis or endothelial dysfunction in psoriasis? Mol Cell Biochem 2015;400:207-12. [PMID: 25421412 DOI: 10.1007/s11010-014-2277-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
52 Park HY, Jun CD, Jeon SJ, Choi SS, Kim HR, Choi DB, Kwak S, Lee HS, Cheong JS, So HS, Lee YJ, Park DS. Serum YKL-40 levels correlate with infarct volume, stroke severity, and functional outcome in acute ischemic stroke patients. PLoS One 2012;7:e51722. [PMID: 23272150 DOI: 10.1371/journal.pone.0051722] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]